

**From:** [BIO Access & Reimbursement Policy](#)  
**To:** [HRSA Paperwork](#)  
**Subject:** [EXTERNAL] Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program ICR Submission  
**Date:** Monday, October 6, 2025 3:33:18 PM  
**Attachments:** [BIO Comment- 340B Enrollment Recertification ICR\\_FINAL\\_10.6.25.pdf](#)

---

To HRSA Information Collection Clearance Officer,

Please find attached Biotechnology Innovation Organization (BIO)'s comments on the Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, OMB No. 0915-0327-Revision. Should you have any questions, please do not hesitate to contact us at 202-962-9200.

Best,

**Melody Calkins**  
*Director, Healthcare Policy*

—

**Biotechnology Innovation Organization (BIO)**  
1201 New York Ave., NW Suite 1300  
Washington, DC 20005

—

202.962.6659 [direct](#) | 630.649.8063 [mobile](#)

**CAUTION:** This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.